drugset / Trial / NCT07527923

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

NCT07527923 ↗

Phase 1 Recruiting 144 enrolled Regeneron Pharmaceuticals
RandomizedSequentialQuadruple-blindTreatment

Summary

This study will test a study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B). REGN20423 is a study medicine that is only used in clinical studies. REGN20423 has not previously been studied in humans. The study is looking at: * What side effects REGN20423 might cause * How much REGN20423 is in the blood at different times * How well REGN20423 works in adults with atopic dermatitis * Whether the body makes antibodies against REGN20423 * How the body changes after having REGN20423, which can help researchers understand why REGN20423 works better in some people than others * What the best dose of REGN20423 is

Timeline

Start
2026-05-22
Primary completion
2028-06-23
Completion
2028-06-23

Drugs

EvaluationDrugModalityDoseRoute
Subject REGN20423 Unknown — —

Indications